The Latest Analyst Ratings for SpringWorks Therapeutics
Portfolio Pulse from Benzinga Insights
In the past 3 months, 4 analysts have published their opinions on SpringWorks Therapeutics (NASDAQ:SWTX) stock, with 3 bullish and 1 somewhat bullish ratings. The company has an average 12-month price target of $89.0, up 61.82% from the previous average of $55.0.
June 06, 2023 | 9:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
SpringWorks Therapeutics (NASDAQ:SWTX) has received 3 bullish and 1 somewhat bullish ratings from 4 analysts in the past 3 months. The average 12-month price target is $89.0, up 61.82% from the previous average.
The positive analyst ratings and the significant increase in the average 12-month price target suggest that the stock is likely to perform well in the short term. The bullish sentiment from the majority of the analysts indicates a positive outlook for the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100